KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$336.67
−0.61%Aug 3, 2026, 11:00 UTC
Krystal Biotech reported financial results for the second quarter ended June 30, 2026, with $119.2 million in global VYJUVEK revenue and $1.1 billion in cash and investments.